SIDEBAR MENU CLOSE
Awards

Winners

Year

City

Winner
2022 Barcelona [18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial

E. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, L. Boeckxstaens1, J. Dekervel3, T. Vandamme4,5, W. Lybaert5, B. Van den Broeck6, P. M. Clement7, K. Geboes8, E. Van Cutsem3, S. Stroobants9, C. Verslype3, G. Bormans2, C. M. Deroose1;

1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 2Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, 4Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, 5Oncology, NETwerk Antwerpen-Waasland CoE, Antwerpen, BELGIUM, 6Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, 7General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM, 8Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM, 9Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.
2021 Virtual Enhanced Therapeutic Effect of the Albumin-Binding [177Lu]Lu-Ibu-DAB-PSMA as Compared to [177Lu]Lu-PSMA-617 – A Preclinical Therapy Study

V. Tschan1, F. Borgna1, R. Schibli1,2, C. Müller1,2;

1Paul Scherrer Institute, 5232 Villigen-PSI, SWITZERLAND, 2ETH Zurich, 8093 Zurich, SWITZERLAND.
2020 Virtual Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: results of a phase 2 trial

G. Paganelli1, S. Severi1, M. Sansovini1, S. Nicolini1, I. Grassi1, F. von Eyben2, V. Conteduca1, M. Monti1, F. Foca1, G. Gurioli1, M. Celli1, F. Matteucci1, U. De Giorgi1;

1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST IRCCS, Meldola (FC), ITALY, 2Center of Tobacco Control Research, Odense M, DENMARK.
2019 Barcelona Changes in synaptic density in relation to tau deposition in prodromal Alzheimer’s disease: a dual protocol PET-MR study

C. H. R. J. Vanhaute1, J. Ceccarini2, L. Michiels3, S. Sunaert4, R. Lemmens3, L. Emsell4, M. Vandenbulcke5, K. Van Laere2;

1Nuclear Medicine and molecular imaging, Department of Geriatric Psychiatry, University Hospitals Leuven; department of imaging and pathology, Catholic University Leuven, Leuven, BELGIUM, 2Nuclear Medicine and molecular imaging, University Hospitals Leuven; department of imaging and pathology, Catholic University Leuven, Leuven, BELGIUM, 3Department of Neurology, University Hospitals Leuven; Laboratory for neurobiology, Catholic University Leuven; Center for Brain and disease research, VIB-KU Leuven, Leuven, BELGIUM, 4Department of Imaging and pathology, Translational MRI; Catholic University Leuven, Leuven, BELGIUM, 5Department of Geriatric Psychiatry, University Hospitals Leuven, Leuven, BELGIUM..
2018 Düsseldorf Terbium-161 for PSMA-Targeted Radionuclide Therapy of Prostate Cancer

C. Mueller1, C. A. Umbricht1, N. Gracheva1, V. J. Tschan1, G. Pellegrini2, P. Bernhardt3, J. R. Zeevaart4, U. Koester5, R. Schibli1, N. P. van der Meulen1;

1Paul Scherrer Institute, Villigen-PSI, SWITZERLAND, 2Vetsuisse Faculty, University of Zurich, Zurich, SWITZERLAND, 3University of Gothenburg, Gothenburg, SWEDEN, 4Necsa, Pretoria, SOUTH AFRICA, 5Insitut Laue-Langevin, Grenoble, FRANCE.
2017 Vienna PSMA-targeting alpha-Radiation therapy with 225Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control

C. Kratochwil1, F. Bruchertseifer2, F. L. Giesel1, C. Apostolidis2, U. Haberkorn1, A. Morgenstern2;

1University Hospital Heidelberg, Heidelberg, GERMANY, 2EC-JRC, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY.
2016 Barcelona Secondary glioblastoma multiforme – local alpha emiters targeted therapy with 213Bi-DOTA-substance P

L. Królicki1, A. Morgenstern2, J. Kunikowska1, H. Koziara3, B. Królicki3, M. Jakuciński4, D. Pawlak5, C. Apostolidis2, F. Bruchertseifer2;

1 Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland, 2 European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany, 3 Department of Neurosurgery, Institute of Psychiatry and Neurology, Warsaw, Poland, 4 Department of Nuclear Medicine, Brodnowski Hospital, Warsaw, Poland, 5 Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND.
2015  Hamburg Feasibility of Affibody molecule-based PNA-mediated pretargeting

A. Honarvar et al.,

Uppsala University, Uppsala, SWEDEN.
2014  Gothenburg Visualising Parasympathetic Denervation in Parkinson’s Disease – [11C]donepezil PET for Imaging Acetylcholinesterase Density in Peripheral Organs (Part I)

P. Borghammer et al.Aarhus University Hospital, Aarhus, DENMARK.
2013  Lyon A new route toward enhancing the uptake of [111In/177Lu-DOTA,Leu15]MG11 in CCK2R-positive xenografts in mice

A. Kaloudi1, B. A. Nock1, E. Lymperis1, P. J. Marsouvanidis1,2, E. P. Krenning2, M. de Jong2,3, T. Maina-Nock1;1Molecular Radiopharmacy, INRASTES, NCSR Demokritos, Athens, GREECE, 2Department of Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, 3Department of Radiology, Erasmus MC, Radiology, NETHERLANDS.
2012  Milan Detection of prostate cancer using 68Ga-labelled bombesin analogue BAY 86-7548 in patients undergoing radical prostatectomy

H. Minn2,5, E. Kähkönen1, I. Jambor2,3, J. Kemppainen2,4, K. Lehtiö5, J. Silén2, A. Kuisma5, P. Luoto2, T. Tolvanen2, K. Alanen6, T. Grönroos2, M. Kallajoki6, A. Roivainen2, N. Schäfer7, R. Schibli8, M. Dragic8, A. Johayem9, R. Valencia10, S. Borkowski10;1Department of Surgery, Division of Urology, Turku University Hospital, Turku, Finland, 2Turku PET Centre, University of Turku, Turku, Finland, 3Department of Diagnostic Radiology, University of Turku, Turku, Finland, 4Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland, 5Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland, 6Department of Pathology, Turku University Hospital, Turku, Finland , 7Department of Medical Oncology and Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, 8Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland , 9Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland, 10Bayer Pharma AG, Berlin, Germany
2011  Birmingham Longitudinal imaging of transplanted islets in a rat model with SPECT

K. Andralojc, M. Brom, L. Claessens-Joosten, D. Bos, W. Oyen, O. Boerman, M. Gotthardt;Radboud University & Medical Center Nijmegen, NETHERLANDS
2010  Vienna VEGF Immuno-PET with 89Zr-ranibizumab during sunitinib treatment

M. N. Lub-de Hooge, W. B. Nagengast, J. A. Gietema, S. F. Oosting, M. A. de Korte, F. Warnders, H. Timmer-Boscha, G. A. Hospers, J. R. de Jong, W. F. den Dunnen, H. Hollema, R. A. J. O. Dierckx, E. G. E. de Vries;University Medical Center Groningen, Groningen, NETHERLANDS
2009  Barcelona Development of an improved amyloid probe, [11C]AZD2184. From pre-clinical to clinical in vivo PET measurements in AD patients

J. Andersson1, K. Varnäs1, Z. Cselényi2, B. Gulyás1, B. Swahn3, S. Finnema1, S. Nyberg2, L. Farde2, C. Halldin1;1Karolinska Institutet, Stockholm, SWEDEN, 2AstraZeneca Pharmaceuticals Neuroscience Clinical, Södertälje, SWEDEN, 3Department of Medicinal Chemistry AstraZeneca R&D, Södertälje, SWEDEN
2008  Munich Intravesical α-radioimmunotherapy with Bi-213-anti-EGFR-MAb defeats human bladder carcinoma in xenografted nude mice

B. Pfost1, C. Seidl1, M. Autenrieth2, D. Saur3, F. Bruchertseifer4, A. Morgenstern4, M. Schwaiger1, R. Senekowitsch-Schmidtke1

1Department of Nuclear Medicine, Technische Universität München, München, GERMANY, 2Department of Urology, Technische Universität München, München, GERMANY, 3II. Medizinische Klinik und Poliklinik, Technische Universität München, München, GERMANY, 4European Commission, JRC, Institute for Transuranium Elements, Karlsruhe, GERMANY
2007  Copenhagen Converging evidence for specific neurotoxic effects of ecstasy on the thalamus: [123I]β-CIT SPECT and advanced MRI studies

M. de Win et al.University Hospital Amsterdam, Amsterdam, The Netherlands
2006  Athens Early predictive value of positron emission tomography with [18F]-fluorodeoxyglucose for the pathologic complete response of primary tumor in breast cancer patients treated by neoadjuvant chemotherapy

A. Berriolo-Riedinger et alCentre G.F. Leclerc, Dijon, France
2005  Istanbul A comparison of amphetamine induced changes in agonist and antagonist radioligand binding potential on the dopamine D2 receptor in primate brain

N. Seneca, S. Finnema, M. Ichise, B. Gulyas, H. Wikstrom, R. Innis, L. Farde, C. Halldin (Stockholm, Bethesda, Groningen)
2004  Helsinki 99mTC Interleukin-2 (99m TC-IL2) Scintigraphy for Imaging Vulnerable Atherosclerotic Plaques

A. Signore, A. Annovazzi, E. Bonnano, M. Arca, C. D’Alessandria, A. Marcoccia, L. Spagnoli, F. Violi, F. Scopinaro, G. De Toma (Rome)
2003  Amsterdam Radioimmunotherapy with Lutetium-177-DOTA-Rituximab: a Phase I/II-Study in Patients with Follicular and Mantle Cell Lymphoma. An interim Analysis

F. Forrer, A. Lohri, H.Uusijärvi, G. Moldenhauer, J. Chen, R. Herrmann, E. Nitzsche, H. Mäcke, J.Müller-Brand (Basel, Liestal, Gothenburg)
2002  Vienna Combined [11C]Raclopride-PET and voxel based morphometry analysis in early Huntington´s disease: separating between functional and morphological alterations

F.D. Juengling, J. Karitzky, C. Solbach, J. Kassubek, C. Saft, B. Heinen, S.N. Reske, T. Kioschies, K. Henkel (Ulm)
2001 Naples [11C]MADAM – a highly suitable radioligand for examination of the serotonin transporter with PET

C. Halldin, D. Guilloteau, J. Tarkiainen, J. Sóvágó, B. Gulyás, J. Sandell, P. Emond, J. Vercouillie, S. Chalon, J. Hiltunen, L. Farde
2000 Paris Partial reversibility and gender differences in the toxic effects of MDMA (‘ecstasy’) on brain serotonin neurons

L. Renemann, J. Booij , K. De Bruin , F.A. De Wolff , W. van den Brink, G.J. Den Heeten (Amsterdam)
1999 Barcelona Low- versus high-dose radioimmunotherapy with humanized anti-CD20 antibodies in a broad spectrum of B-cell associated malignancies

T.M. Behr , B. Wörmann, M. Gramatzki, M. Béhé, F. Griesinger, W. Hiddemann, D.M. Goldenberg, W. Becker (Göttingen)
1998 Berlin Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer

G. Paganelli, C. DeCicco , M. Cremonesi, A. Luini, M. Bartolomei, C. Grana , G. Prosco , V. Galimberti, P. Calza, G. Viale, U. Veronesi (Milan)
1997 Glasgow Coronary revascularization improves survival and left ventricular function in patients with chronic coronary artery disease and dysfunctional but viable myocardium at thallium-201 imaging

A. Cuoculo, E. Nicolai, M. Petretta, L. Pace, S. Cardei, A. Varrone, B. Trimarco, M. Salvatore (Naples)
1996 Copenhagen Relationship between clinical features of Parkinson’s disease and presynaptic dopamine transporter function assessed with I-123 IPT and SPECT

K. Tatsch, P.D. Mozley, J. Schwarz, R. Linke, O. Pogarell, R.S. Fieber, K. Hahn, H.F. Kung (Munich)
1995 Brussels Imaging of 5-HT1a receptors in human brain using (C-11)Way-100635 and PET

V. Pike, J. McCarron, S. Hume, S. Ashworth, J. Opcka-Juffry, A. Lammerstma, K. Poole, A. Malizia, C. Bench, P. Grasby, I. Cliffe, A. Fletcher (London)
1994 Düsseldorf Recombinant human interleukin-1: a potential agent to image infectious foci

J. van der Laken, I.C. Boerman, W.J.G. Oyen, M.T.P. van de Ven, J. Makarewicz, R.A.M.J. Claessens, J.W.M. van der Meer, F.H.M. Corstens (Nijmegen)
1993 Lausanne Comparison of 123-I-alpha-methyl tyrosine SPECT and 11C-L-methionine PET in patients with brain tumors: initial results

K.J. Langen, B. Hamacher, K. Ziemons, T. Kuwert, U. Braun, H. Herzog, J.C.W. Kiwit, B. Nebeling, G. Stöcklin, H.W. Müller- Gärtner (Düsseldorf, Jülich)
1992 Lisbon Preparation of (11C)ß-CIT, a new ligand for imaging cocaine binding sites in vivo by PET

C. Halldin, L. Farde, L. Müller, P. Karlsson, J.L. Neumeyer, Y. Gao, R. Milius, H. Hall, C.G. Swahn (Stockholm, Natick)
1991 Vienna PET studies of human cerebral malignancy with (2-11C) thymidine (TRD) and (18F)FDG

T. van der Borght, S. Pauwels, L. Lambotte, L.D. Labor, S. De Maeght, G. Stroobandt, C. Laterre (Brussels)
1990 Amsterdam Ventilation and perfusion in a single image

J.J.P. de Lima, M.F.R. Botelho, A.M.S. Pereira, J.A.S. Rafael, M.A.T. Marques, A.J. Pinto, F. Godinho, M.C. Pereira, M.F. Baganha (Aveiro, Coimbra, Lisbon)

Year

City

Winner
2022 Barcelona PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [177Lu]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603)
J. Buteau1, A. Martin2, L. Emmett3, A. Iravani4, S. Sandhu1, A. M. Joshua3, R. J. Francis5, A. Y. Zhang2, A. M. Scott6, S. Lee6, A. Azad1, M. McJannett7, M. R. Stockler8, S. Williams1, I. D. Davis9, M. S. Hofman1;
1Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 2NHMRC Clinical Trials Centre, Sydney, AUSTRALIA, 3St-Vincent’s Hospital, Sydney, AUSTRALIA, 4Washington University, St. Louis, MO, UNITED STATES OF AMERICA, 5Sir Charles Gairdner Hospital, Perth, AUSTRALIA, 6Austin Health, Melbourne, AUSTRALIA, 7ANZUP, Sydney, AUSTRALIA, 8NHMRC CTC, Sydney, AUSTRALIA, 9Monash University and Eastern Health, Melbourne, AUSTRALIA.

Next generation PET/CT imaging in meningioma using the novel SSTR-targeting peptide 18F-SiTATE – first clinical experiences
M. Unterrainer1, S. C. Kunte1, L. M. Unterrainer1, A. Delker1, S. Lindner1, M. Brendel1, A. Holzgreve1, W. G. Kunz1, C. C. Cyran1, J. Ricke1, K. Jurkschat2, C. Waengler3, B. Waengler3, R. Schirrmacher4, M. Niyazi1, J. Tonn1, L. Beyer1, P. Bartenstein1, N. L. Albert1;
1University of Munich, Munich, GERMANY, 2TU Dortmund, Dortmund, GERMANY, 3University of Heidelberg, Heidelberg, GERMANY, 4University of Alberta, Edmonton, AB, CANADA.

[18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial
E. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, L. Boeckxstaens1, J. Dekervel3, T. Vandamme4,5, W. Lybaert5, B. Van den Broeck6, P. M. Clement7, K. Geboes8, E. Van Cutsem3, S. Stroobants9, C. Verslype3, G. Bormans2, C. M. Deroose1;
1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 2Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, 4Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, 5Oncology, NETwerk Antwerpen-Waasland CoE, Antwerpen, BELGIUM, 6Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, 7General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM, 8Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM, 9Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.
2021 Virtual Longitudinal Evaluation Of The First Mutant Huntingtin PET Radioligand As A Marker For mHTT Lowering Therapies For Huntington’s Disease
D. Bertoglio1, J. Verhaeghe1, S. De Lombaerde1,2, F. Zajicek1, T. Vasilkovska1, A. Miranda3, A. Gaertner4, B. Huscher4, A. Kakoulidou4, I. Cardaun4, A. Cornelius4, T. Schwagarus4, A. Van der Linden1, S. Stroobants1,2, Y. Wang5, M. Skinbjerg5, C. Dominguez5, V. Khetarpal5, L. Liu5, I. Munoz-Sanjuan5, J. Bard5, S. Staelens1;
1University of Antwerp, Wilrijk, BELGIUM, 2Antwerp University Hospital, Edegem, BELGIUM, 3University of Antwerp, Antwerpen, BELGIUM, 4Evotec SE, Hamburg, GERMANY, 5CHDI Management/CHDI Foundation, Los Angeles, CA, UNITED STATES OF AMERICA.

A pilot study comparing 18F-FDG PET/CT and 68Ga-FAPI PET/CT for initial staging of early operable and locally advanced breast cancers
P. Chandra, K. Senthil, M. Sridev, G. Chandran, J. Kumar, M. Merlin, P. Priya, J. Sangeetha, S. Nath;
MIOT international, Chennai, INDIA.

68Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung disease
C. Schmidkonz1, J. Distler2, C. Treutlein3, A. Atzinger1, O. Prante1, P. Ritt1, T. Götz1, T. Bäuerle1, M. Cordes1, M. Köhner1, T. Kuwert1, A. Ramming2, G. Schett2, C. Bergmann2;
1University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY, 2University Hospital Erlangen, Department of Rheumatology, Erlangen, GERMANY, 3University Hospital Erlangen, Department of Radiology, Erlangen, GERMANY.
2020 Virtual Ratiometric relationship between γH2AX imaging and Lutetium-177 is predictive of survival following radionuclide therapy in vivo
E. O’Neill, G. M. Dias, B. Cornelissen;
University of Oxford, Oxford, UNITED KINGDOM.

[18F]AlF-NOTA-octreotide PET imaging: Pharmacokinetics, biodistribution, and head-to-head comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
E. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, J. Dekervel3, E. Van Cutsem3, C. Verslype3, K. Van Laere1, G. Bormans2, C. M. Deroose1;
1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 2Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM.

[177Lu]Lu-PSMA-617 in low-volume metastatic hormone sensitive prostate cancer: a prospective pilot study
B. Prive1, S. M. B. Peters1, C. H. J. Muselaers1, P. Zamecnik1, M. J. R. Janssen1, T. W. J. Scheenen1, M. W. Konijnenberg1, J. Verzijlbergen1, W. R. Gerritsen1, N. Mehra1, D. M. Somford2, J. A. Van Basten2, I. M. Van Oort1, J. Sedelaar1, J. O. Barentsz1, S. Heskamp1, M. Gotthardt1, J. Witjes1, J. Nagarajah1;
1Radboudumc, Nijmegen, NETHERLANDS, 2Canisius Wilhelmina Hospital, Nijmegen, NETHERLANDS.
2019 Barcelona Fluorine-18 Labeled FAPI-Tracers For PET Imaging
T. Lindner1, A. Altmann1,2, F. L. Giesel1, C. Kratochwil1, C. Kleist1, S. Kraemer1, J. Debus3,4, W. Mier1, U. Haberkorn1,2,5;
1Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, 2Clinical Cooperation Unit Nuclear Medicine, German Cancer research Center (DKFZ), Heidelberg, GERMANY, 3Dept. of Radiation Oncology, University Hospital Heidelberg, Heidelberg, GERMANY, 4Clinical Cooperation Unit Radiation Oncology, German Cancer research Center (DKFZ), Heidelberg, GERMANY, 5Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, GERMANY.

First Results of Targeted Alpha Peptide Receptor Radionuclide Therapy Using Ac-225 DOTATOC for Progressive Metastatic Neuroendocrine Neoplasms
H. R. Kulkarni, J. Zhang, A. Singh, C. Schuchardt, R. P. Baum;
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, GERMANY.

Tandem PSMA Radioligand Therapy Using Ac-225 and Lu-177 in Advanced Prostate Cancer: Safety and Efficacy
H. R. Kulkarni, J. Zhang, A. Singh, A. Mishra, C. Schuchardt, R. P. Baum;
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, GERMANY.

Imaging DNA Damage in vivo following [177Lu]Lu-DOTATATE therapy in a model of pancreatic neuroendocrine cancer
E. O’Neill1, V. Kersemans1, P. Allen1, S. Terry2, J. Baguña Torres1, S. Smart1, B. Quan Lee1, N. Falzone1, K. Vallis1, M. Konijnenberg3, M. de Jong3, J. Nonnekens3, B. Cornelissen1;
1University of Oxford, Oxford, UNITED KINGDOM, 2King’s College London, London, UNITED KINGDOM, 3Erasmus MC, Rotterdam, NETHERLANDS.

First extensive preclinical evaluation of PSMA-specific tracers for prostate cancer radioligand therapy
E. Ruigrok, S. U. Dalm, E. de Blois, N. van Vliet, D. C. van Gent, J. Haeck, C. de Ridder, D. Stuurman, M. W. Konijnenberg, W. M. van Weerden, M. de Jong, J. Nonnekens;
Erasmus MC, Rotterdam, NETHERLANDS.
2018 Düsseldorf Clinical outcome of 121 patients after PSMA-targeted radioguided surgery for early biochemical recurrent prostate cancer
M. Kroenke1, T. Horn2, I. Rauscher1, S. Robu3, M. Schottelius3, H. Wester3, T. Maurer2, W. Weber1, M. Eiber1;
1Department of Nuclear medicine, Klinikum rechts der Isar, TUM, Munich, GERMANY, 2Department of Urology, Klinikum rechts der Isar, TUM, Munich, GERMANY, 3Chair of Pharmaceutical Radiochemistry, Department of Chemistry, TUM, Munich, GERMANY.

A Complete Response following A Single Treatment with 225Ac-RPS-074 in LNCaP Xenografts
J. M. Kelly1, A. Amor-Coarasa1, S. Ponnala1, N. A. Thiele2, A. Nikolopoulou1, C. Williams Jr.1, J. Urgiles1, J. J. Wilson2, J. W. Babich1;
1Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, 2Cornell University, Ithaca, NY, UNITED STATES OF AMERICA.

First evidence for a dose-response relationship in hepatic holmium-166 radioembolization
R. Bastiaannet, C. van Roekel, M. L. J. Smits, R. C. G. Bruijnen, J. F. Prince, H. W. A. M. de Jong, M. G. E. H. Lam; ;
University Medical Center Utrecht, Utrecht, NETHERLANDS.

Development Of Stroma-targeted Theranostics Based On Inhibitors Of Fibroblast Activating Protein
T. Lindner, A. Loktev, A. Altmann, F. Giesel, C. Kratochwil, W. Mier, U. Haberkorn;
University Hospital Heidelberg, Heidelberg, GERMANY.

Novel targeted radionuclide therapy approach enhances response to immune checkpoint blockade in murine melanoma
R. Hernandez, R. Patel, J. Grudzinski, E. Aluicio-Sarduy, R. Brown, R. Sriramaneni, J. W. Engle, P. M. Sondel, Z. S. Morris, J. P. Weichert;
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.
2017 Vienna Dual-labeled PSMA-11 for PET/CT imaging and precise fluorescence guided intraoperative identification of prostate cancer
A. Baranski1, M. Schäfer1, U. Bauder-Wüst1, M. Roscher1, J. Schmidt1, E. Stenau1, T. Simpfendörfer2, L. Maier-Hein1, B. Hadaschik3, U. Haberkorn2, K. Kopka1, M. Eder4,1,5;
1German Cancer Research Center, Heidelberg, GERMANY, 2University Hospital, Heidelberg, GERMANY, 3University Hospital, Essen, GERMANY, 4University Hospital, Freiburg, GERMANY, 5German Cancer Consortium, Heidelberg, GERMANY.

First experience using LMI1195 in patients with the suspicion of pheochromocytoma or paraganglioma
C. Rischpler1, A. M. Schlitter1, M. Herz1, B. Yousefi1, A. von Werder1, R. Tauber1, T. Maurer1, K. Scheidhauer1, S. Robinson2, C. Orlandi2, S. G. Nekolla1, M. Schwaiger1;
1Technical University Munich, Munich, GERMANY, 2Lantheus Medical Imaging, N. Billerica, MA, UNITED STATES OF AMERICA.

TSPO-PET for high-grade glioma imaging using the novel ligand [18F]GE-180 – first in human results in the course of radiotherapy
M. Unterrainer1, D. Fleischmann1, S. Lindner1, A. Brunegraf1, F. Vettermann1, L. Vomacka1, M. Brendel1, R. Rupprecht2, C. Belka1, P. Bartenstein1, M. Niyazi1, N. Albert1;
1Ludwig-Maximilian-University Munich, München, GERMANY, 2University of Regensburg, München, GERMANY.

Monitoring tumor PD-L1 expression with microSPECT/CT during radiotherapy
S. Heskamp, J. D. M. Molkenboer-Kuenen, G. W. Sandker, P. J. Wierstra, J. Bussink, O. C. Boerman;
Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.

Radiocobalt-labeled anti-HER1 affibody molecule DOTA-ZEGFR:2377 for imaging of low HER1 expression in prostate cancer pre-clinical model
B. Mitran1, J. Garousi1, M. Rosestedt1, E. Lindström1, K. G. Andersson2, S. Ståhl2, J. Löfblom2, V. Tolmachev1, A. Orlova1;
1Uppsala University, Uppsala, SWEDEN, 2KTH-Royal Institute of Technology, Stockholm, SWEDEN.
2016 Barcelona 68Ga-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels < 2 ng/mL
F. Ceci, P. Castellucci, T. Graziani, C. Fonti, F. Lodi, S. Boschi, S. Fanti; Service of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

SPECT/CT imaging of the PD-1/PD-L1 immune checkpoint pathway in syngeneic murine tumor models
S. Heskamp, J. D. M. Molkenboer-Kuenen, R. H. A. M. van de Vondervoort, O. C. Boerman; Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.

Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct ZVEGFR2-Bp2
B. Mitran1, R. Güler2, E. Lindström1, F. Fleetwood2, V. Tolmachev1, S. Ståhl2, A. Orlova1, J. Löfblom2;  1Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of Technology, Stockholm, SWEDEN.

Prognostic significance of molecular and imaging biomarkers in primary brain tumors
E. Lopci1, M. Riva1, L. Olivari2, F. Raneri2, A. Bizzi3, B. Fernandes1, P. Navarria1, F. Pessina1, M. Roncalli4, L. Bello1, A. Chiti4;  1Humanitas Clinical and Research Hospital, Milano, ITALY, 2University of Milan, Milano, ITALY, 3Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, ITALY, 4Humanitas University, Milano, ITALY.

Value of F-DOPA PET in the long term follow up of radionecrotic brain metastases after radiosurgery: comparison with MRIF. Cicone1, L. Carideo1, C. Scaringi2, A. Romano3, A. Bozzao3, G. Minniti2, F. Scopinaro1; 1Unit of Nuclear Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 2Unit of Radiation Oncology, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 3Unit of Neuroradiology, Sant’Andrea Hospital, “Sapienza” University or Rome, Rome, ITALY.
2015  Hamburg A phage display derived stabilised bicyclic peptide targeting MMP-14 shows high imaging contrast in small animal PET imaging
A. M. Eder, S. Pavan, U. Bauder-Wüst, K. van Rietschoten, L. Baldassarre, U. Schierbaum, O. Seibert, K. Leotta, S. Campbell, H. Harrison, C. Stace, E. Walker, U. Haberkor, K. Kopka, D. P. Teufel; Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

Tc-99m-CXCL8 SPECT to image disease activity in inflammatory bowel disease
E. Aarntzen, D. De Jong, R. Hermsen, J. Drenth, O. Boerman, W. Oyen; Radboud UMC, Nijmegen, Netherlands

Blunted striatal dopamine release in cannabis dependence
E. van de Giessen, J. Weinstein, C. Cassidy, M. Haney, M. Slifstein, A. Abi-Dargham; Columbia University College of Physicians and Surgeons/New York State Psychiatric Institute, New York, United States of America.

Synergistically Enhanced Tumor Uptake via Dual-Targeting of CD105 and EGFR Using a “Click” Heterodimer
R. Hernandez, H. Luo, H. Hong, S. A. Graves, R. J. Nickles, W. Cai; University of Wisconsin-Madison, Madison, United States of America.

Metastatic control probability in patients with prostate cancer metastatic to bone treated 186Re-HEDP
A. M. Denis-Bacelar, A. Divoli, S. Chittenden, Y. Du, G. D. Flux; Institute of Cancer Research, London, United Kingdom
2014  Gothenburg Quantitative analyses at Baseline and Interim PET evaluation for response assessment and outcome definition in patients with Malignant Pleural Mesothelioma (MPM)
Egesta Lopci; Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), HUMANITAS (Rozzano), Milano, Italy

A comparison of EGFR-targeted and non-targeted 177Lu-labeled gold nanoparticles (AuNPs) for localized radiation treatment of breast cancer xenografts in athymic mice
Simmyung Yook; University of Toronto, Leslie Dan Faculty of Pharmacy, Pharmaceutical Sciences, Toronto, Canada

Validation and applications for SNAP-tag imaging of bacterial infection.
Bethany Mills; University of Nottingham, Nottingham, United Kingdom

Non-FDG-avid areas inside a tumour mass in Paediatric Hodgkin Lymphoma (PHL) patients – A new risk factor?
Lars Kurch; University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany

The QUEST Study: Correlating metabolic response with 90Y PET dosimetry for the treatment of metastatic liver cancer with radioembolisation
Kathy P. Willowson; University of Sydney, Sydney, Australia
2013  Lyon Development and pre-clinical evaluation of a new glucose-dependent insulinotropic polypeptide (GIP) based radioligand for PET imaging of a broad spectrum of neuroendocrine tumors
Eleni Gourni; University Hospital, Department of Nuclear Medicine, Freiburg, GERMANY

Synergistic anti-cancer response to chemotherapy and 177Lu-labelled APOMAB® radio immunotherapy in a preclinical model of lung cancer
Alexander Staudacher; Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, AUSTRALIA

Tc99m labelled S-HYNIC Certolizumab Pegol for selecting patients for anti-TNFα treatment: a biodistribution and dosimetric study
Bieke Lambert; Department of Nuclear Medicine, Ghent University Hospital, BELGIUM

PET-guided radiotherapy planning in prostate cancer patients
Egesta Lopci; Humanitas Clinical and Research Center, Milan, ITALY

Evaluation of primary tumour and regional lymph node metastases with FDG PET/CT in breast cancer patients: prone versus supine position
Suzana Teixeira; Dutch Cancer Institute, Amsterdam, NETHERLANDS.

Year

City

Winner
2022 Barcelona Best Oral Presentation Technologists
Using a novel long-axial field-of-view (LAFOV) PET/CT system for dual tracer scanning with [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT for PSMA-therapy assessment
R. Schepers, K. Zeimpekis, M. Viscione, A. Rominger, A. Afshar-Oromieh, I. Alberts;
Inselspital, Bern, SWITZERLAND.
Second Best Oral Presentation Technologists
A Tale of Serendipity from Misadministration
M. Butfield, M. Vyas1,2, A. M. Henderson, A. Rowlings, J. Fagan, R. Joseph;
1Unitec Institute of Technology, Auckland, NEW ZEALAND, 2Mercy Radiology, Auckland, NEW ZEALAND.
Third Best Oral Presentation Technologists
Development of a Framework for Radiographer Online Clinical Education (FORCE): the specific strand of Nuclear Medicine within this European Project
P. Costa1, J. Atutornu2, P. Bezzina3, N. Dalen4, J. Huhtanen5, M. Jaronen6, T. Saila6, B. Kraus7, L. Rainford8, K. Matthews8;
1Nuclear Medicine Department, School of Health – Polytechnic Institute of Porto (ESS|P.Porto), Porto, PORTUGAL, 2School of Health and Sports Sciences – University of Suffolk, Suffolk, UNITED KINGDOM, 3Faculty of Health Sciences – University of Malta, Msida, MALTA, 4Department of Health and Functioning – Western Norway University of Applied Sciences, Bergen, NORWAY, 5Health and Well-being, Rehabilitation, Oral Health Care and Diagnostic Services – Turku University of Applied Sciences, Turku, FINLAND, 6Social Services and Health Care – Tampere University of Applied Sciences, Tampere, FINLAND, 7University of Applied Sciences FH Campus Wien, Wien, AUSTRIA, 8School of Medicine – University College Dublin, Dublin, IRELAND.
Best e-Poster Presentation  Technologists
Value of continuous blood pressure monitoring in the evaluation of maximal hyperemia during myocardial perfusion imaging with Rubidium-82 PET/CT
A. Tegelaar – Kuiper1, S. S. Koenders1,2, J. A. van Dalen3, P. L. Jager1, J. D. van Dijk1;
1Department of Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS, 2Technical Medical Centre, University of Twente, Enschede, NETHERLANDS, 3Department of Medical Physics, Isala Hospital, Zwolle, NETHERLANDS.
2021 Virtual Best Oral Presentation Technologists
Multiple-Time-Point 2-[18F]FDG PET/CT: Adrenal Glands Normal Metabolic Pattern Characterization
I. Rodrigues1, A. Martins1, S. Carmona2, M. J. Vieira2, L. Oliveira1;
1Grupo Joaquim Chaves Saúde – Lisbon, Portugal/ Portuguese Red Cross Health School – Lisbon, Portugal, Lisbon, PORTUGAL, 2Grupo Joaquim Chaves Saúde – Lisbon, Portugal, Lisbon, PORTUGAL.
Second Best Oral Presentation Technologists
Comparative study of Dopamine transporter Imaging between a conventional camera and an innovative 3D-ring hybrid gamma-camera: technologist’s point of view
J. Dessoubrais, P. Oudot, F. Clouse, M. Bailly;
Regional Hospital Center of Orleans, Orléans, FRANCE.
Third Best Oral Presentation Technologists
Learning from our mistakes: a teaching tool to improve the quality of Nuclear Medicine Technologist’s practices
E. A. Lemos Pereira, A. Garcia, A. Malaia, M. Fateixa;
NuclearMed – Hospital Particular Almada, Almada, PORTUGAL.
Best e-Poster Presentation  Technologists
PET/CT reconstruction study using 2 mm voxel size for improved image quality
S. Rep1,2, P. Tomse1, L. Jensterle1, K. Zaletel1,3, L. Lezaic1,3;
1Department for Nuclear medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of health sciences, Medical imaging and radiotherapy department, Ljubljana, SLOVENIA, 3Faculty of medicine, Ljubljana, SLOVENIA.
2020 Virtual Best Oral Presentation Technologists
Evaluation of data-driven gating for 68Ga-DOTATOC PET-CT in patients with neuroendocrine tumors
J. Sigfridsson1, H. Romelin1, E. Lindström2,3, S. Kvernby2,3, I. Velikyan1,3, A. Sundin1,3, M. Lubberink1,3;
1PET Centre, Uppsala University Hospital, Uppsala, SWEDEN, 2Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN, 3Radiology & Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.
Second Best Oral Presentation Technologists
Dose reduction in FDG-PET by reconstruction optimization using resolution modelling
A. Tegelaar-Kuiper1, S. Koenders1,2, D. Koopman1, P. G. Sanches3, B. N. Vendel1, H. Arkies1, J. A. van Dalen4;
1Department of Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS, 2Technical Medical Centre, University of Twente, Enschede, NETHERLANDS, 3Health Systems, Philips Benelux, Eindhoven, NETHERLANDS, 4Department of Medical Physics, Isala Hospital, Zwolle, NETHERLANDS.
Third Best Oral Presentation Technologists
Ventilation scintigraphy: is it really safe now with COVID-19 pandemic?
S. Mendes, I. Ferreira, J. Isidoro, G. Costa, P. Soeiro, J. P. Lima;
Hospitais da Universidade de Coimbra, Coimbra, PORTUGAL.
Best e-Poster Presentation  Technologists
Is there a role for 99mTc-PSMA in times of 18F-PSMA?
T. Oliveira, B. Beier, J. Sailer, P. Peloscheck, M. Hoffmann;
Radiology Center, Vienna, AUSTRIA.
2019 Barcelona Best Oral Presentation Technologists
Further Reduction Of [18F]-fdg Activity Applied In Clinical Routine For State-of-the-art 3d Tof Pet/ct Systems: Is It Feasible?
J. Pilz, L. Hehenwarter, J. Holzmannhofer, G. Schweighofer-Zwink, C. Pirich;
Second Best Oral Presentation Technologists
Amyloid Positron Emission Tomography (PET) scanning: Process and pathway pitfalls and review
L. Alves, B. Williams, D. Vilic, Z. Win
Third Best Oral Presentation Technologists
Review of protocol change for SLN injections in patients with breast cancer
P. J. Campbell, H. Sharman, C. Caro
Best e-Poster Presentation  Technologists
Influence of intravenous diuretics on the detectability of local prostate cancer recurrence in 68Ga-PSMA-11 PET/CT
L. Dijkstra, I. Alberts, G. Prenosil, A. Rominger, A. Afshar-Oromieh;
Second Best e-Poster Presentation Technologists
Glomerular filtration rate: Comparison of two tracers
L. Janus, T. Andersen, K. Thilsing-Hansen, D. Roholdt, C. Led, P. Andersen, H. Thomsen, O. Gerke, P. Høilund-Carlsen, J. Simonsen;
Third Best e-Poster Presentation Technologists
Lymphoscintigraphy and sentinel node localization in gynaecological cancers into practice: a UK single-centre protocol
L. Pereira, K. Brooks, T. Barnden, O. Devaja, A. Corrigan
2018 Düsseldorf Best Oral Presentation
Semi-quantitative criteria for the diagnosis of the myocarditis using 99mTc-Pyrophosphate SPECT/CT
J. Ilyushenkova, S. Sazonova, K. Zavadovsky
2nd Nominee for Best Oral Presentation
Usefulness of SPECT for the semiquantitative assessment of regional 123I MIBG myocardial uptake in heart failure: comparison between iterative reconstruction (OSEM) versus filtered back projection
A. Ruzza, I. Andreoli, G. Romagna, P. Basile, L. Filippi, O. Bagni
3rd Nominee for Best Oral Presentation
Comparison of Gastric Emptying Results Using 60min, 90min and 120min Protocol – A Retrospective Study
D. Teixeira Maçarico, C. Laurins, A. Nicol
Best e-Poster Award
99mTc-MAA SPECT/CT-based dosimetry in SIRT: Why personalized dosimetry matters – A retrospective study
L. Esteves, B. Collette, E. El Darazi, G. Verset, V. Lucidi, S. Goldman, R. Moreno-Reyes
2nd Nominee for Best e-Poster Presentation
Standardised Uptake Value & Hounsfield Unit in lumber spine & head of the femur for Alkaptonuria measured from 18F-NaF PET/CT bone scan
E. H. M. A. Alawadhi, S. Vinjamuri, J. Gallagher, R. Lakshminarayan
3rd Nominee for Best e-Poster Presentation
Incidence of asymptomatic nephroptosis detected by 99mTc-MAG3 renogram
S. Mendes, R. Silva, G. Costa, P. Soeiro, C. Barbosa, J. Rodrigues, I. Ferreira, J. P. Lima
2017 Vienna Best Oral Presentation – CET Award
18F-FDG PET/CT in pediatric lymphoma patients: the role of technologist
M.Ciaccio, C. Nava, D. Bonacina, M. Maurizio, A. Perri, A. Renaioli, S. Morzenti, L. Guerra, C. Crivellaro
2nd Nominee for Best Oral Presentation
Improving alignment between 18F-FDG PET and CT scans by controling breathing movements during the CT-scan
K. Lehnskov, C. P. Jønsson, L. B. Katz, D. A. Riisberg
3rd Nominee for Best Oral Presentation
A review of thyroid blockade strategies used in paediatric I123MIBG scintigraphy, and an evaluation of their relative effectiveness
B. Thurlow, T. Melhuish, P. Leanne, E. Morris, S. Johns, M. Guy, S. King, L. Biassoni
Best Poster Award
Residual Activity Correction Successfully Adjusts Myocardial Blood Flow Measurements in Time-efficient 13N-ammonia Myocardial Perfusion PET/CT
P. A. Doodeman, S. V. Lazarenko, F. M. van der Zant, M. Wondergem, R. J. J. Knol
2nd Nominee for Best Poster Presentation
Comparison of MPI SPECT/CT scans acquired with LEHR collimator and reduced time IQ SPECT system
S. Ferreira, P. Begley, M. Jessop, A. Aldous, N. Eftychiou, N. Singh, S. Dizdarevic, E. Sousa
3rd Nominee for Best Poster Presentation
A cost effective protocol for increasing patient throughout using a combination of half time imaging with 99mTc Tetrofosmin and Regadenoson in Stress Myocardial Perfusion Imaging
P. J. Turner, T. Watts, F. Whittingham
2016 Barcelona Best Oral Presentation – META Award
The diagnostic quality of 18-F-FDG PET images from the PET/MR in comparison with the PET/CT
E. Voets, M. G. W. Visser, F. M. Mottaghy, S. Vöö
2nd Nominee for Best Oral Presentation
First clinical experience with SUVmax cuantification by a dedecated breast PET compared to PET-CT.
R. SANCHEZ JURADO, J. FERRER REBOLLEDA, M. COZAR SANTIAGO, J. AGUILAR BARRIOS, R. BRISA VAZQUEZ, A. VICEDO GONZALEZ
3rd Nominee for Best Oral Presentation
A European phantom study to cross-calibrate myocardial 123I-mIBG scintigraphy
E. Poel, D. O. Verschure, K. Nakajima, K. Okuda, B. L. F. van Eck-Smit, G. A. Somsen, H. J. Verberne
Best Poster Award
Preoperative localisation of hyperfunctioning parathyroid glands; A preliminary comparison between99mTc-sestaMIBI / 123I scintigraphy and 18F-fluorocholine PET/CT
E. Jansen, M. Wondergem, F. M. Van der Zant, R. J. J. Knol
2nd Nominee for Best Poster Presentation
Calculating the Effective Dose from the CT Component of a SPECT/CT Study
A. M. Cheetham, G. Havariyoun, E. Kalogianni, D. Ruiz, L. Devlin, N. Gulliver, A. Eccles, N. Mulholland, G. Vivian
3rd Nominee for Best Poster Presentation
Upgrading Siemens software from Caredose mAs to both Caredose mAs and kV: Impact on patient radiation doses
B. Dall, C. Schulze, C. S. Knudsen, A. E. Ljunggren
2015  Hamburg Best Oral Presentation – META Award
Radiation Dose to the Eye Lens: Does Positioning Really Matter?
C. Baun, K. Falch, K. D. Nielsen, S. Shanmuganathan, O. Gerke, P. Hoeilund-Carlsen
2nd Nominee for Best Oral Presentation
Adaptation of 13N-NH3 and 18F-FDG Imaging Protocols for sarcoidosis for new scanner technology
C. Abreu, J. O’Doherty, S. Barrington, S. Pereira, L. Alves, J. John, P. Schleyer
3rd Nominee for Best Oral Presentation
Radionuclide therapy of metastatic melanoma with benzamide derivate I-131-BA100 after patient stratification with F-18-DOPA
F. O. Spohn, K. Kunze, F. Giesel, W. Mier, U. Haberkorn, C. Kratochwil
Best Poster Award
Evaluation of the quality of neuroimaging features as Alzheimer’s Disease biomarkers
F. Lucena, T. F. Vaz, J. Pé-Leve, A. S. Ribeiro, L. Lacerda, N. Silva, D. Nutt, J. McGonigle, H. A. Ferreira
2nd Nominee for Best Poster Presentation
Comparative retrospective study of peptide receptor radionuclide therapy (PRRT) with Y-90-DOTATOC and Y-90-DOTATATE in neuroendocrine tumours (NET)
M. Marx, H. Plagge, C. Winkler, Y. Zhao, U. Lützen, M. Zuhayra
3rd Nominee for Best Poster Presentation
Biodistribution Assessment of Sodium Pamidronate and Methylene Diphosphonate for Rats Bone Scintigraphy Images
T. S. C. Camozzato, A. Z. P. De Souza, M. Tizon, S. J. Garcia, V. F. Dutra1, T. G. Costa
2014  Gothenburg Best Oral Presentation – META Award
Role of Advanced Practitioner in the clinical setting of a multi-disciplinary clinic for alpha emitting 223Radium-dichloride therapy for bone metastases in castration-resistant prostate cancer
M. Jessop, A. Staker, K. Day, M. Aplin, N. Ryan, H. Cripps, A. Hosur, N. Singh, A. Robinson, S. Dizdarevic
2nd Nominee for Best Oral Presentation
Is it possible to use Teflon cannulae for Radionuclide Equilibrium Angiography?
M. Casanova Martins, C. Humphreys, A. Queiroz, C. Gascoigne, P. Ali
3rd Nominee for Best Oral Presentation
Quantitative assessment of 18-FDG PET/CT and dbPET: Relationship with Breast Cancer prognostic factors
R. Sanchez Jurado, M. Devis Saiz, A. Vicedo Gonzalez, J. Ferrer Rebolleda, J. Pamos Navas
Best Poster Award Research
Practice development in nuclear medicine technologists
P. Chilra, S. Gnesin,G.Allenbach, J. Prior, C. Marques, C. Masias-Valdés, F. Descombes, L. Vieira, J. A. P. Jorge
2nd Nominee for Best Poster Presentation
Comparison of Imaging Angle and Analysis Software on the Measurement of Left ventricular Ejection Fraction
W-C. Way, C.Huang, J. Lin, S.Wang
3rd Nominee for Best Poster Presentation
Interobserver and intraobserver variation of phase analysis results in ECG-gated myocardial perfusion SPECT related to repeated reconstructions
M. Hakala, T. Koivumaki, M. Hakulinen, M. Kokkonen, A. Leinonen, T. Laitinen
2013  Lyon Best Oral Presentation
How low can you go: Dose-reduction in Low-Dose CT-scans for attenuation correction in myocardial perfusion imaging
N. de Wit, B.J. Vermolen, P.J.G. Peeters, A.M. Scholtens, J.C.M. Buijs, H.W.A.M. de Jong
2nd Nominee for Best Oral Presentation
PET/CT imaging of head-neck patients: Comparison of a one-step protocol and a two-step protocol
C. S. Knudsen, A. Ljunggren, T. Beyer, F. Andersen, T. L. Klausen, K. Cappelen, A. K. Berthelsen, S. Holm, A. Loft
3rd Nominee for Best Oral Presentation
Simultaneous PET/MR in breast cancer-first results
C. Meisinger, I. Dregely, S. Schachoff, M. Schwaiger
Best Poster Award
Optimal number of iterations and attenuation correction method for the quantification of liver radioactivity on 99mTc-GSA SPECT/CT imaging
Y. Nakamura, S. Tomiguchi, N. Katsuda, M. Hashida
2nd Nominee for Best Poster Presentation
Evaluation of the basic characteristics of the cardiac focusing-collimators
A. Niwa, S. Abe, T. Odagawa, N. Fujita, H. Kono, T. Kumazawa, Y. Fujita, K. Kato
3rd Nominee for Best Poster Presentation
Causes and Actions in Relation to Defaulting Patients
T. Godskesen

Year

City

Winner
2022 Barcelona EJNMMI Most Cited Paper Award
Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy.
François Lucia, Dimitris Visvikis, Marie-Charlotte Desseroit, Omar Miranda, Jean-Pierre Malhaire, Philippe Robin, Olivier Pradier, Mathieu Hatt & Ulrike Schick, Eur J Nucl Med Mol Imaging 45,768–786 (2018). doi: 10.1007/s00259-017-3898-7

EJNMMI Best Paper Award
Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings.
Haojun Chen, Liang Zhao, Dan Ruan, Yizhen Pang, Bing Hao, Yaqing Dai, Xiurong Wu, Wei Guo, Chunlei Fan, Jingxun Wu, Weipeng Huang, Qin Lin, Long Sun & Hua Wu, Eur J Nucl Med Mol Imaging 48, 73–86 (2021). doi: 10.1007/s00259-020-04940-6

EJNMMI Best Paper Award
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Paul Blanc-Durand, Simon Jégou, Salim Kanoun, Alina Berriolo-Riedinger, Caroline Bodet-Milin, Françoise Kraeber-Bodéré, Thomas Carlier, Steven Le Gouill, René-Olivier Casasnovas, Michel Meignan & Emmanuel Itti, Eur J Nucl Med Mol Imaging 48, 1362–1370 (2021). doi: 10.1007/s00259-020-05080-7

EJNMMI Best Paper Award
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer – the SALT trial -.
H. E. Jansen, Y. J. L. Bodar, G. J. C. Zwezerijnen, D. Meijer, J. P. van der Voorn, J. A. Nieuwenhuijzen, M. Wondergem, T. A. Roeleveld, R. Boellaard, O. S. Hoekstra, R. J. A. van Moorselaar, D. E. Oprea-Lager & A. N. Vis, Eur J Nucl Med Mol Imaging 48, 509–520 (2021). doi: 10.1007/s00259-020-04974-w

EJNMMI Research Best Paper Award
Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study.
Christos Sachpekidis, Annette Kopp-Schneider, Jessica C. Hassel & Antonia Dimitrakopoulou-Strauss, EJNMMI Res 11,89 (2021). doi: 10.1186/s13550-021-00832-4

EJNMMI Physics Best Paper Award
Artificial intelligence for reduced dose 18F-FDG PET examinations: a real-world deployment through a standardized framework and business case assessment.
Katia Katsari, Daniele Penna, Vincenzo Arena, Giulia Polverari, Annarita Ianniello, Domenico Italiano, Rolando Milani, Alessandro Roncacci, Rowland O. Illing & Ettore Pelosi, EJNMMI Phys 8, 25 (2021). doi: 10.1186/s40658-021-00374-7

EJNMMI Radiopharmacy and Chemistry Best Paper Award
Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair.
Brooke L. McNeil, Andrew K. H. Robertson, Winnie Fu, Hua Yang, Cornelia Hoehr, Caterina F. Ramogida & Paul Schaffer, EJNMMI radiopharm. chem. 6, 6 (2021). doi: 10.1186/s41181-021-00121-4

European Journal of Hybrid Imaging Best Paper Award
Development of artificial intelligence in epicardial and pericoronary adipose tissue imaging: a systematic review.
Lu Zhang, Jianqing Sun, Beibei Jiang, Lingyun Wang, Yaping Zhang & Xueqian Xie, European J Hybrid Imaging 5, 14 (2021). doi: 10.1186/s41824-021-00107-0
2021 Virtual EJNMMI Most Cited Paper Award
Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
Ali Afshar-Oromieh, Tim Holland-Letz, Frederik L. Giesel, Clemens Kratochwil, Walter Mier, Sabine Haufe, Nils Debus, Matthias Eder, Michael Eisenhut, Martin Schäfer, Oliver Neels, Markus Hohenfellner, Klaus Kopka, Hans-Ulrich Kauczor, Jürgen Debus & Uwe Haberkorn, Eur J Nucl Med Mol Imaging 44, 1258–1268 (2017). doi: 10.1007/s00259-017-3711-7

EJNMMI Best Paper Award
18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases
Chunxia Qin, Fang Liu, Tzu-Chen Yen & Xiaoli Lan, Eur J Nucl Med Mol Imaging 47, 1281–1286 (2020). doi: 10.1007/s00259-020-04734-w

EJNMMI Best Paper Award
Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer
Haojun Chen, Yizhen Pang, Jingxun Wu, Liang Zhao, Bing Hao, Jing Wu, Jihong Wei, Siming Wu, Long Zhao, Zuoming Luo, Xuehua Lin, Chengrong Xie, Long Sun, Qin Lin & Hua Wu, Eur J Nucl Med Mol Imaging47,1820–1832 (2020). doi: 10.1007/s00259-020-04769-z

EJNMMI Best Paper Award
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
Elin Pauwels, Frederik Cleeren, Térence Tshibangu, Michel Koole, Kim Serdons, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Koen Van Laere, Guy Bormans & Christophe M. Deroose, Eur J Nucl Med Mol Imaging 47, 3033–3046 (2020). doi: 10.1007/s00259-020-04918-4

EJNMMI Research Best Paper Award
Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images
Matteo Bauckneht, Rita Lai, Alberto Miceli, Daniela Schenone, Vanessa Cossu, Maria Isabella Donegani, Stefano Raffa, Anna Borra, Stefano Marra, Cristina Campi, Annamaria Orengo, Anna Maria Massone, Alberto Tagliafico, Claudia Caponnetto, Corrado Cabona, Angelina Cistaro, Adriano Chiò, Silvia Morbelli, Flavio Nobili, Gianmario Sambuceti, Michele Piana & Cecilia Marini, EJNMMI Res 10, 23 (2020). doi: 10.1186/s13550-020-0607-5

EJNMMI Physics Best Paper Award
Evaluation of a new multipurpose whole-body CzT-based camera: comparison with a dual-head Anger camera and first clinical images
Cédric Desmonts, Mohammed Abdeldjalil Bouthiba, Blandine Enilorac, Catherine Nganoa, Denis Agostini & Nicolas Aide, EJNMMI Phys7, 18 (2020). doi: 10.1186/s40658-020-0284-5

EJNMMI Radiopharmacy and Chemistry Best Paper Award
Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target
Melissa E. Rodnick, Carina Sollert, Daniela Stark, Mara Clark, Andrew Katsifis, Brian G. Hockley, D. Christian Parr, Jens Frigell, Bradford D. Henderson, Monica Abghari-Gerst, Morand R. Piert, Michael J. Fulham, Stefan Eberl, Katherine Gagnon & Peter J. H. Scott, EJNMMI radiopharm. chem. 5, 25 (2020). doi: 10.1186/s41181-020-00106-9

European Journal of Hybrid Imaging Best Paper Award
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
Sungmin Woo, Soleen Ghafoor, Anton S. Becker, Sangwon Han, Andreas G. Wibmer, Hedvig Hricak, Irene A. Burger, Heiko Schöder & Hebert Alberto Vargas, European J Hybrid Imaging 4, 16 (2020). doi: 10.1186/s41824-020-00085-9
2020 Virtual EJNMMI Most Cited Paper Award
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
Thomas Pyka, Shozo Okamoto, Marielena Dahlbender, Robert Tauber, Margitta Retz, Matthias Heck, Nagara Tamaki, Markus Schwaiger, Tobias Maurer & Matthias Eiber, Eur J Nucl Med Mol Imaging43,2114–2121 (2016). doi: 10.1007/s00259-016-3435-0

EJNMMI Best Paper Award
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
Cristina Müller, Christoph A. Umbricht, Nadezda Gracheva, Viviane J. Tschan, Giovanni Pellegrini, Peter Bernhardt, Jan Rijn Zeevaart, Ulli Köster, Roger Schibli & Nicholas P. van der Meulen, Eur J Nucl Med Mol Imaging46,1919–1930 (2019). doi: 10.1007/s00259-019-04345-0

EJNMMI Best Paper Award
First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Jie Zang, Xinrong Fan, Hao Wang, Qingxing Liu, Jingnan Wang, Hui Li, Fang Li, Orit Jacobson, Gang Niu, Zhaohui Zhu & Xiaoyuan Chen, Eur J Nucl Med Mol Imaging 46, 148–158 (2019). doi: 10.1007/s00259-018-4096-y

EJNMMI Best Paper Award
Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors
Simone Krebs, Neeta Pandit-Taskar, Diane Reidy, Bradley J. Beattie, Serge K. Lyashchenko, Jason S. Lewis, Lisa Bodei, Wolfgang A. Weber & Joseph A. O’Donoghue, Eur J Nucl Med Mol Imaging 46, 677–685 (2019).
doi: 10.1007/s00259-018-4193-y

EJNMMI Research Best Paper Award
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
Lucas Goldfarb, Boris Duchemann, Kader Chouahnia, Laurent Zelek & Michael Soussan, EJNMMI Res 9, 8 (2019). doi: 10.1186/s13550-019-0473-1

EJNMMI Physics Best Paper Award
Accelerated SPECT image reconstruction with FBP and an image enhancement convolutional neural network
Martijn M. A. Dietze, Woutjan Branderhorst, Britt Kunnen, Max A. Viergever & Hugo W. A. M. de Jong, EJNMMI Phys 6, 14 (2019). doi: 10.1186/s40658-019-0252-0

EJNMMI Radiopharmacy and Chemistry Best Paper Award
[11C]Carbon monoxide: advances in production and application to PET radiotracer development over the past 15 years
Carlotta Taddei & Victor W. Pike, EJNMMI radiopharm. chem.4,25 (2019). doi: 10.1186/s41181-019-0073-4

European Journal of Hybrid Imaging Best Paper Award
Cardiac PET/MRI—an update
Rischpler, S. G. Nekolla, G. Heusch, L. Umutlu, T. Rassaf, P. Heusch, K. Herrmann & F. Nensa, European J Hybrid Imaging3, 2 (2019). doi: 10.1186/s41824-018-0050-2
2019 Barcelona EJNMMI Most Cited Paper Award
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
Ali Afshar-Oromieh, Eleni Avtzi, Frederik L. Giesel, Tim Holland-Letz, Heinz G. Linhart, Matthias Eder, Michael Eisenhut, Silvan Boxler, Boris A. Hadaschik, Clemens Kratochwil, Wilko Weichert, Klaus Kopka, Jürgen Debus & Uwe Haberkorn, Eur J Nucl Med Mol Imaging (2015) 42: 197. doi:10.1007/s00259-014-2949-6

EJNMMI Best Paper Award
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
Madhav Prasad Yadav, Sanjana Ballal, Madhavi Tripathi, Nishikant Avinash Damle, Ranjit Kumar Sahoo, Amlesh Seth & Chandrasekhar Bal, Eur J Nucl Med Mol Imaging (2017) 44: 81. doi: 10.1007/s00259-016-3481-7

EJNMMI Best Paper Award
Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET
Danielle J. Vugts, Chris Klaver, Claudia Sewing, Alex J. Poot, Kevin Adamzek, Seraina Huegli, Cristina Mari, Gerard W. M. Visser, Ibai E. Valverde, Gilles Gasser, Thomas L. Mindt & Guus A. M. S. van Dongen,Eur J Nucl Med Mol Imaging (2017) 44: 286. doi: 10.1007/s00259-016-3499-x

EJNMMI Best Paper Award
Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
Kyoichi Kaira, Tetsuya Higuchi, Ichiro Naruse, Yukiko Arisaka, Azusa Tokue, Bolag Altan, Satoshi Suda, Akira Mogi, Kimihiro Shimizu, Noriaki Sunaga, Takeshi Hisada, Shigehisa Kitano, Hideru Obinata, Takehiko Yokobori, Keita Mori, Masahiko Nishiyama, Yoshihito Tsushima & Takayuki Asao, Eur J Nucl Med Mol Imaging (2018) 45: 56. doi: 10.1007/s00259-017-3806-1

EJNMMI Research Best Paper Award
PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects
Erica M. Richards, Paolo Zanotti-Fregonara, Masahiro Fujita, Laura Newman, Cristan Farmer, Elizabeth D. Ballard, Rodrigo Machado-Vieira, Peixiong Yuan, Mark J. Niciu, Chul Hyoung Lyoo, Ioline D. Henter, Giacomo Salvadore, Wayne C. Drevets, Hartmuth Kolb, Robert B. Innis & Carlos A. Zarate Jr, EJNMMI Research, Volume 8, Article number: 57 (2018). doi: 10.1186/s13550-018-0401-9

EJNMMI Physics Best Paper Award
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
Anna Sundlöv, Johan Gustafsson, Gustav Brolin, Nadja Mortensen, Rebecca Hermann, Peter Bernhardt, Johanna Svensson, Michael Ljungberg, Jan Tennvall & Katarina Sjögreen Gleisner, EJNMMI Physics, Volume 5, Article number: 12 (2018). doi: 10.1186/s40658-018-0210-2

EJNMMI Radiopharmacy and Chemistry Best Paper Award
Production of novel diagnostic radionuclides in small medical cyclotrons
Mateusz Adam Synowiecki, Lars Rutger Perk & J. Frank W. Nijsen, EJNMMI Radiopharmacy and Chemistry, Volume 3, Article number: 3 (2018). doi: 10.1186/s41181-018-0038-z

European Journal of Hybrid Imaging Best Paper Award
The role of hybrid bone SPECT/CT imaging in the work-up of the limping patient: a symptom-based and joint-oriented review
H. K. Mohan, K. Strobel, W. van der Bruggen, G. Gnanasegaran, W. U. Kampen, T. Kuwert, T. Van den Wyngaert & F. Paycha, European Journal of Hybrid Imaging, Volume 2, Article number: 8 (2018). doi: 10.1186/s41824-018-0026-2
   
2018 Düsseldorf Most Cited Paper – EJNMMI
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience, Eur J Nucl Med Mol Imaging (2014) 41: 887. DOI 10.1007/s00259-013-2660-z, Author Block: Afshar-Oromieh, U. Haberkorn, H. P. Schlemmer, et al.

Best Paper – EJNMMI
Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT, Eur J Nucl Med Mol Imaging (2017) 44: 92. DOI 10.1007/s00259-016-3490-6, Author Block: Johannes Schwenck, Hansjoerg Rempp, Gerald Reischl, et al.

Best Paper – EJNMMI
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients, Eur J Nucl Med Mol Imaging (2017) 44: 678. DOI 10.1007/s00259-016-3573-4, Author Block: Frederik L. Giesel, Hadaschik, J. Cardinale, et al.

Best Paper – EJNMMI
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour, Eur J Nucl Med Mol Imaging (2017) 44: 941. DOI 10.1007/s00259-017-3631-6, Author Block: Christian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, et al.

Best Paper – EJNMMI Physics
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey, EJNMMI Physics (2017) 4:28. DOI 10.1186/s40658-017-0193-4, Author Block: Katarina Sjögreen Gleisner, Emiliano Spezi, Pavel Solny, et al.

Best Paper – EJNMMI Research
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617, EJNMMI Research (2017) 7:9. DOI 10.1186/s13550-017-0257-4, Author Block: Christoph A. Umbricht, Martina Benešová, Raffaella M. Schmid, et al.

Best Paper – EJNMMI Radiopharmacy and Chemistry
47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes, EJNMMI Radiopharmacy and Chemistry (2017) 2:5. DOI 10.1186/s41181-017-0024-x, Author Block: Katharina A. Domnanich, Cristina Müller, Martina Benešová, et al.

Best Paper – European Journal of Hybrid Imaging
Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer, European Journal of Hybrid Imaging, EJNMMI Multimodality Journal (2017) 1:2. DOI 10.1186/s41824-017-0006-y, Author Block: Ichiei Kuji, Tomohiko Yamane, Akira Seto, et al.
2017 Vienna Most Cited Paper – EJNMMI
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur J Nucl Med Mol Imaging (2013) 40: 486. doi: 10.1007/s00259-012-2298-2, Author Block: Afshar-Oromieh, A., Malcher, A., Eder, M. et al.

Best Paper – EJNMMI
68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients”, Eur J Nucl Med Mol Imaging (2016) 43: 34. doi:10.1007/s00259-015-3188-1, Author Block: Sterzing, F., Kratochwil, C., Fiedler, H. et al.

Best Paper – EJNMMI
Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score, Eur J Nucl Med Mol Imaging (2016) 43: 397. doi:10.1007/s00259-015-3240-1, Author Block: Verburg, F.A., Pfister, D., Heidenreich, A. et al.

Best Paper – EJNMMI
Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer, Eur J Nucl Med Mol Imaging (2016) 43: 70. doi: 10.1007/s00259-015-3206-3, Author Block: Freitag, M.T., Radtke, J.P., Hadaschik, B.A. et al.

Best Paper – EJNMMI Physics
Physics of pure and non-pure positron emitters for PET: a review and a discussion, EJNMMI Phys (2016) 3:8. doi: 10.1186/s40658-016-0144-5, Author Block: Conti, M., Eriksson, L.

Best Paper – EJNMMI Research
The relationship between endogenous thymidine concentrations and [18F]FLT uptake in a range of preclinical tumour models, EJNMMI Research (2016) 6:63. doi:10.1186/s13550-016-0218-3, Author Block: Heinzmann, K. et al.

Best Paper – EJNMMI Radiopharmacy and Chemistry
New protein deposition tracers in the pipeline, EJNMMI Radiopharmacy and Chemistry (2016) 1:11. doi: 10.1186/s41181-016-0015-3, Author Block: Jovalekic, A. et al.
2016 Barcelona Most Cited Paper – EJNMMI
Prognostic value of metabolic tumor burden on F-18-FDG PET in nonsurgical patients with non-small cell lung cancer, Eur J Nucl Med Mol Imaging (2012) 39: 27. doi:10.1007/s00259-011-1934-6, Author Block: Liao, S., Penney, B.C., Wroblewski, K. et al.

Best Paper – EJNMMI
The diagnostic value of PET/CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate, Eur J Nucl Med Mol Imaging (2015) 42: 197. doi:10.1007/s00259-014-2949-6, Author Block: Afshar-Oromieh, A., Avtzi, E., Giesel, F.L. et al.

Best Paper – EJNMMI
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors, Eur J Nucl Med Mol Imaging (2015) 42: 5. doi:10.1007/s00259-014-2893-5, Author Block: Bodei, L., Kidd, M., Paganelli, G. et al.

Best Paper – EJNMMI
F-18]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease, Eur J Nucl Med Mol Imaging (2015) 42: 1052. doi:10.1007/s00259-015-3035-4, Author Block: Harada, R., Okamura, N., Furumoto, S. et al.

Most Downloaded Paper – EJNMMI Physics
Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency, EJNMMI Phys (2015) 2: 10. doi:10.1186/s40658-015-0113-4, Author Block: Högberg, J., Rizell, M., Hultborn, R. et al.

Most Cited Paper – EJNMMI Research
Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET, EJNMMI Res (2012) 2: 28. doi:10.1186/2191-219X-2-28, Author Block: Notni, J., Pohle, K. & Wester, H.
2015 Hamburg EJNMMI Most Cited Paper
Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data, Eur J Nucl Med Mol Imaging (2011) 38:138–152 DOI 10.1007/s00259-010-1603-1, Author Block: V. Schulz, I. Torres-Espallardo, S. Renisch, Z. Hu, N. Ojha et al.

EJNMMI Best Paper
Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer, Eur J Nucl Med Mol Imaging (2014) 41:50–58 DOI 10.1007/s00259-013-2530-8, Author Block: J.Y. Choi, S. Hyup Hyun, H. Kyung Ahn, Hojoong Kim, Myung-Ju Ahn, Keunchil Park et al.

EJNMMI Best Paper
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease, Eur J Nucl Med Mol Imaging (2014) 41:816–826 DOI 10.1007/s00259-013-2681-7, Author Block: V.L. Villemagne, S. Furumoto, M.T. Fodero-Tavoletti, R. S.Mulligan, John Hodges et al.

EJNMMI Best Paper
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging (2014) 41:11–20 DOI 10.1007/s00259-013-2525-5, Author Block: A. Afshar-Oromieh, C. M. Zechmann, A. Malcher, Matthias Eder, Michael Eisenhut et al.
2014 Gothenburg EJNMMI Best Technical Paper
Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT, January 2013, Volume 40, Issue 1, pp 12-21, Dr. Carl von Gall

EJNMMI Best Basic Science Paper
Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology, January 2013, Volume 40, Issue 1, pp 125-132, Dr. Nobuyuki Okamura

EJNMMI Best Clinical Paper
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, April 2013, Volume 40, Issue 4, pp 486-495, Dr. Afshar-Oromieh

EJNMMI Most Cited Paper
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0, January 2010, Volume 37, Issue 1, pp 181-200, Prof. Ronald Boellaard

 

Year

City

Winner
2022 Barcelona David Kersting (Essen, Germany)
This website uses cookies. Learn more